Jupiter Neurosciences (NASDAQ:JUNS) Posts Earnings Results, Misses Expectations By $0.01 EPS

Jupiter Neurosciences (NASDAQ:JUNS) announced its quarterly earnings results on Thursday. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01), FiscalAI reports. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.23 million.

Jupiter Neurosciences Stock Performance

Shares of NASDAQ JUNS traded down $0.01 during midday trading on Friday, hitting $0.34. 40,053 shares of the stock traded hands, compared to its average volume of 88,968. The company has a market cap of $12.26 million, a PE ratio of -1.25 and a beta of 2.16. Jupiter Neurosciences has a one year low of $0.31 and a one year high of $3.33. The business has a 50 day moving average price of $0.38 and a two-hundred day moving average price of $0.78.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Jupiter Neurosciences

An institutional investor recently raised its position in Jupiter Neurosciences stock. Geode Capital Management LLC grew its position in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 27.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,641 shares of the company’s stock after acquiring an additional 28,826 shares during the quarter. Geode Capital Management LLC owned about 0.39% of Jupiter Neurosciences worth $135,000 as of its most recent filing with the Securities & Exchange Commission.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.